Michelle Hoffman

Can an overload of patent applications lead to the US' demise as a scientific leader?

Text sirtuins are the new kinases, according to a presentation given last month at the JP Healthcare Investors Conference in San Francisco by Sirtis CEO Christoph Westphal.

The most significant early-stage discovery to hit the journals in late 2007 were the dual announcements from two independent research groups that they turned adult human skin cells into cells with properties that are seemingly identical with human embryonic stem (hES) cells.

Fixing FDA lies in the hands of the government, but is the president-to-be paying attention?

Drug makers, drug inspectors, and drug consumers need to demand that new drugs be effective.

"May you live in interesting times," goes the allegedly ancient Chinese curse. Well, these have been "interesting times" indeed for those working in the pharmaceutical industry.

Sanofi-aventis entered into an agreement with Chinese authorities allowing Sanofi to construct a vaccine-manufacturing plant in Shenzhen municipality.

Information technology is the glue that should unify a company while ironically, it enables further fragmentation. Experts talk about the successes and challenges for IT in helping a company function efficiently.

Thanks to the media, Nobel Laureates are underrated, undervalued, and simply uncool.

The senior director of Oracle's Life Sciences Business Unit tackles some of the technical issues regarding regulatory standardization, software integration, and the trend toward virtualization, among other things. Do you have something to ask Arvindh Balakrishnan? Click here to submit your questions.

Novartis opened a new $180-million tableting facility in late October in Singapore and announced its intention to construct a $700-million cell-culture facility in the country.

Courts are denying the terminally ill access to experimental drugs, leaving many with no options.

In an age of "pre-existing conditions," can a new bill help patients get the treatment they need?

Schering-Plough announced today that a consent decree filed against the company in May, 2002, had been dissolved by the US District Court for the District of New Jersey in Newark.

By vetoing stem cell research funding, the President is vetoing potentially life-saving treatments.

Infrastructure must be in place before jumping into outsourcing.

A new guidance issued by the US Food and Drug Administration earlier this month advises companies on how to treat polymorphic drug compounds?those that exhibit multiple structural forms?in filing abbreviated new drug applications.

More than five million US adults import prescription drugs from other countries, according to a survey conducted by the Pharmaceutical Research and Manufacturers of America.

Thirty years ago, the world was a very different place; so was the pharma industry.

Perhaps Congress can help FDA meet its multiple oversight demands.